A population study of 28 general practices in Oxfordshire, UK found that 0.028% of 17,712 non-hysterecto-mized women aged 45-60 years were using systemic unopposed estrogen. This is significantly lower than that reported in the Million Women Study.
GradyD, GebretsadikT, KerlikowskeKHormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol1995; 85: 304-13
2.
WeiderpassE, AdamiHO, BaronJARisk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst1999; 91: 1131-7
3.
WeiderpassE, BaronJA, AdamiHOLow-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet1999; 353: 1824-8
4.
BeralV, BullD, ReevesG; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet2005; 365: 1543-51
BrayF, Dos Santos SilvaI, MollerH, WeiderpassE. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev2005; 14: 1132-42
7.
HamptonNR, ReesMC, LoweDGLevonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod2005; 20: 2653-60
8.
RaudaskoskiTH, LahtiEI, KauppilaAJ, Apaja-SarkkinenMA, LaatikainenTJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol1995; 172: 114-9
9.
Anders sonK, Matts sonLA, RyboG, StadbergE. Intrauterine release of levonorgestrel-a new way of adding pro gestogen in hormone replacement therapy. Obstet Gynecol1992; 79: 963-7
10.
van GeelenJM, van de Wei]erPH, ArnoldsHT. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct2000; 11: 9-14
